Written questions by Gordon.

Whether his Department will ringfence funding for independent patient advocacy services after the abolition of Healthwatch.

The independent complaints advocacy service in the National Health Service is covered by a wider grant for Local Reform and Community Voices and is not a requirement of Healthwatch England or Local Healthwatch. This grant provides funding to local authorities which assists them in meeting statutory duties. This funding will continue to be provided. This grant has not been ringfenced to date and there are no plans to ringfence it, moving forward.

What assessment he has made of the potential merits of extending the provision of Covid vaccinations to people with (a) type 1 diabetes and (b) long term immunosuppressive health conditions.

The Joint Committee on Vaccination and Immunisation (JCVI) is an independent expert committee which reviews the latest data on COVID-19 risks, vaccine safety, and effectiveness and advises the government on eligibility for vaccination and immunisation programmes. The JCVI has published advice for future COVID-19 vaccination campaigns in autumn 2025, spring 2026, autumn 2026, and spring 2027. The government has accepted JCVI advice for autumn 2025. The Government is considering the JCVI’s advice for 2026 and spring 2027 carefully and will respond in due course.The primary aim of the national COVID-19 vaccination programme remains the prevention of serious disease (hospitalisations and deaths) arising from COVID-19. The JCVI assessment indicates that the oldest age cohorts and individuals who are immunosuppressed are the two groups who continue to be at higher risk of serious disease.Therefore, in autumn 2025, a COVID-19 vaccination will be offered to:adults aged 75 years and over;residents in a care home for older adults;individuals aged 6 months and over who are immunosuppressed (as defined in the ‘immunosuppression’ sections of tables 3 or 4 in the COVID-19 chapter of the UK Health Security Agency Green Book).The JCVI has advised that more recent data are needed to assess whether any other population groups under the age of 75 years with specific clinical comorbidities, such as type 1 diabetes, are at similar risk of serious disease as those aged 75 years and over.The JCVI continues to review evidence and may update its advice in future.

What steps he is taking to improve the quality of national primary care data on Young Onset Dementia.

Young onset dementia is defined as dementia diagnosed under the age of 65.The dementia diagnosis rate is not calculated for patients aged under 65 years old. This is because the numbers of patients known to have dementia in the sample population age groups comprising those aged between zero and 64 years old are not large enough for reliable estimates to be made.The dementia diagnosis rate for patients aged 65 years old and over is calculated and published monthly via the Primary Care Dementia Data publication, which is available at the following link: https://digital.nhs.uk/data-and-information/publications/statistical/primary-care-dementia-dataThis publication does include a monthly count of the number of patients aged 65 years old and under who do have a dementia diagnosis on their patient record. This is expressed as a raw count and as a percentage of registered patients aged between zero and 64 years old.

What assessment his Department has made of the potential merits of having a universal screening programme for type 1 diabetes.

I refer the Hon. Member to the answer I gave to the Hon. Member for South Northamptonshire on 25 July 2025 to Question 67791.

What assessment his Department has made of the potential impact of the 10 year health plan on health outcomes for people with type 1 diabetes.

The 10-Year Health Plan aims enhance the care of patients living with type 1 diabetes through shifts in how care is delivered. Hospital to community will enable those living with diabetes to manage their care in the best way for them through the Neighbourhood Health Service, while analogue to digital will make it easier for those living with diabetes to access tailored advice and manage their appointments at a time that suits them. By 2028, patients will be able to manage all their care through the NHS App. People with diabetes will be able to book appointments, manage their medication and prescriptions and view their single-patient record so they can become better advocates for themselves. Patients will be able to access tailored advice through the NHS App on how to manage their diabetes. The App will give patients a doctor in their pocket, and artificial intelligence functionality will enable patients to check their symptoms and find out where to go for further advice or screening as appropriate. Patient care will be personalised through the comprehensive single patient record. When patients attend appointments, clinicians will be able to see all their medical information and history, helping them to make informed diagnoses against co-morbidities and advise patients of their individual risk factor.By 2035, all patients will have access to wearables. Wearables will enable patients and their carers to better manage their care by having access to their health data such as blood pressure and glucose levels. They will also enable remote monitoring to alert a patient’s care team to any issues so that appropriate interventions can be made quickly before they progress.The MyHealth tool will enable remote monitoring, giving patients piece of mind that their condition is being monitored and healthcare professionals will step in if needed.The Neighbourhood Health Service will give those living with diabetes more choice and control of their care. Patients will receive seamless care across services through high-quality care plans. The plan proposes that by 2027, 95% of people with complex needs, including long-term conditions, will have an agreed care plan. More people will be able to access Personal Health Budgets. Patients will be told how much money is available to them and will be supported by their National Health Service team to decide how to spend that money to meet their needs. By 2028 the Diagnosis Connect service will support better self-care. In partnership with the Richmond Group, this service will bring together the NHS and the voluntary sector to help people with new diagnoses manage their care.

What assessment his Department has made of the potential impact of the 10 year health plan on levels of inequality in access to wearable diabetes technology.

The 10 Year Health Plan aims to reduce the prevalence of type 2 diabetes and enhance the care of patients living with diabetes through the delivery of the three shifts. Hospital to community will enable those living with diabetes to manage their care in the best way for them through the Neighbourhood Health Service. Analogue to digital will make it easier for those living with diabetes to access tailored advice and manage their appointments at a time that suits them. Treatment to prevention will make it easier for people to access diabetes screening and support people to make healthier choices to prevent them from developing type 2 diabetes.By 2035, all patients will have access to wearables. Wearables will enable patients and their carers to better manage their care by having access to their health data such as blood pressure and glucose levels. They will also enable remote monitoring to alert a patient’s care team to any issues so that appropriate interventions can be made quickly before they progress.

Whether he plans to bring forward (a) regulations and (b) a licensing regime for practitioners of cosmetic surgery.

All doctors performing cosmetic surgery in the United Kingdom are required to be registered and licensed to practise by the General Medical Council. The Care Quality Commission regulates cosmetic treatments carried out by healthcare professionals in England that involve surgical procedures.The Government is committed to taking action to address longstanding concerns about the safety of the cosmetics sector and is exploring options for further regulation in this area. We will set out the details of our approach in our response to the consultation on the licensing of non-surgical cosmetic procedures in England, which we will publish at the earliest opportunity.

Whether the UK Health Security Agency plans to expand its clinical testing protocols for patients presenting with encephalitis of unknown cause, in the context of the recent detection of West Nile Virus genetic material.

In May 2025, the Animal and Plant Health Agency (APHA) reported fragments of West Nile virus genetic material in a small sample of mosquitoes collected in Nottinghamshire during July 2023, as part of the RADAR surveillance programme. There is no evidence to suggest ongoing circulation of the virus in animals or mosquitoes, and there have been no locally acquired West Nile virus detections in humans in the United Kingdom. The UK Health Security Agency (UKHSA) has assessed the risk to the general public as very low.The UKHSA partners with the Department for Environment, Food and Rural Affairs and the APHA on the surveillance of mosquitoes, birds, horses, and humans for a range of emerging infectious diseases, including West Nile virus.Human health surveillance relevant to the West Nile virus includes routine testing of travellers who have returned from overseas areas affected by West Nile virus with compatible clinical syndromes, including undiagnosed encephalitis.The NHS Blood and Transplant service screens donors returning from affected areas based on their travel history, and partners with the UKHSA on a research study to understand the risk of climate-related emerging infections, including West Nile virus.The UKHSA’s clinical testing protocols require that any undiagnosed human cases of encephalitis are referred to the UKHSA’s Rare and Imported Pathogens Laboratory. They will be routinely tested for West Nile virus, regardless of travel history.Following the detection in mosquitoes, the UKHSA issued a briefing note to National Health Service clinicians nationally on the potential clinical presentation of vector borne diseases, including West Nile virus.The UKHSA Imported Fever Service offers a clinical advisory and testing service to support doctors managing domestic cases of undiagnosed encephalitis. The British Infection Association’s testing guidelines for encephalitis are being updated to include consideration of the West Nile virus.

What steps he is taking to increase public health surveillance following the detection of West Nile Virus genetic material in UK mosquitoes.

In May 2025, the Animal and Plant Health Agency (APHA) reported fragments of West Nile virus genetic material in a small sample of mosquitoes collected in Nottinghamshire during July 2023, as part of the RADAR surveillance programme. There is no evidence to suggest ongoing circulation of the virus in animals or mosquitoes, and there have been no locally acquired West Nile virus detections in humans in the United Kingdom. The UK Health Security Agency (UKHSA) has assessed the risk to the general public as very low.The UKHSA partners with the Department for Environment, Food and Rural Affairs and the APHA on the surveillance of mosquitoes, birds, horses, and humans for a range of emerging infectious diseases, including West Nile virus.Human health surveillance relevant to the West Nile virus includes routine testing of travellers who have returned from overseas areas affected by West Nile virus with compatible clinical syndromes, including undiagnosed encephalitis.The NHS Blood and Transplant service screens donors returning from affected areas based on their travel history, and partners with the UKHSA on a research study to understand the risk of climate-related emerging infections, including West Nile virus.The UKHSA’s clinical testing protocols require that any undiagnosed human cases of encephalitis are referred to the UKHSA’s Rare and Imported Pathogens Laboratory. They will be routinely tested for West Nile virus, regardless of travel history.Following the detection in mosquitoes, the UKHSA issued a briefing note to National Health Service clinicians nationally on the potential clinical presentation of vector borne diseases, including West Nile virus.The UKHSA Imported Fever Service offers a clinical advisory and testing service to support doctors managing domestic cases of undiagnosed encephalitis. The British Infection Association’s testing guidelines for encephalitis are being updated to include consideration of the West Nile virus.

What steps his Department is taking to (a) support and (b) inform healthcare professionals on the potential clinical presentation of West Nile Virus in the UK.

In May 2025, the Animal and Plant Health Agency (APHA) reported fragments of West Nile virus genetic material in a small sample of mosquitoes collected in Nottinghamshire during July 2023, as part of the RADAR surveillance programme. There is no evidence to suggest ongoing circulation of the virus in animals or mosquitoes, and there have been no locally acquired West Nile virus detections in humans in the United Kingdom. The UK Health Security Agency (UKHSA) has assessed the risk to the general public as very low.The UKHSA partners with the Department for Environment, Food and Rural Affairs and the APHA on the surveillance of mosquitoes, birds, horses, and humans for a range of emerging infectious diseases, including West Nile virus.Human health surveillance relevant to the West Nile virus includes routine testing of travellers who have returned from overseas areas affected by West Nile virus with compatible clinical syndromes, including undiagnosed encephalitis.The NHS Blood and Transplant service screens donors returning from affected areas based on their travel history, and partners with the UKHSA on a research study to understand the risk of climate-related emerging infections, including West Nile virus.The UKHSA’s clinical testing protocols require that any undiagnosed human cases of encephalitis are referred to the UKHSA’s Rare and Imported Pathogens Laboratory. They will be routinely tested for West Nile virus, regardless of travel history.Following the detection in mosquitoes, the UKHSA issued a briefing note to National Health Service clinicians nationally on the potential clinical presentation of vector borne diseases, including West Nile virus.The UKHSA Imported Fever Service offers a clinical advisory and testing service to support doctors managing domestic cases of undiagnosed encephalitis. The British Infection Association’s testing guidelines for encephalitis are being updated to include consideration of the West Nile virus.

What steps he is taking to increase bowel cancer screening rates; and whether he plans to increase bowel cancer screening targets.

The National Health Service is in the final stages of changing the screening age for the Bowel Cancer Screening Programme, from those between 60 to 74 years old to those between 50 to 74 years old by 2025, which will increase the numbers being screened.NHS England has updated the programme’s standard for uptake, increasing the acceptable and achievable thresholds, to acknowledge that uptake has increased by approximately 10% since introducing the Faecal Immunochemical Test.A new standard will be introduced to monitor uptake for those aged 60 to 74 years old and those aged 50 to 59 years old. The revised standards will soon be published and available in the public domain. The current standards are available at the following link:https://www.gov.uk/government/publications/bowel-cancer-screening-programme-standards/bowel-cancer-screening-programme-standards-valid-for-data-collected-from-1-april-2018

What assessment his Department has made of the potential merits of a national screening programme for Type 1 Diabetes.

In the United Kingdom, national screening programmes are introduced based on the recommendations of the UK National Screening Committee (UK NSC), an independent scientific advisory committee which advises Ministers and the National Health Service in all four countries on all aspects of population and targeted screening and supports implementation.A proposal for screening for neonatal diabetes mellitus was submitted to the UK NSC via its 2021 annual call process. An evidence-mapping exercise was conducted at that time which concluded that there was not sufficient evidence to recommend screening for this condition.We are aware that the UK NSC received a submission via its 2024 annual call process to consider screening for autoimmune Type 1 Diabetes through blood testing. The UK NSC is currently reviewing all annual call proposals. More information on the annual call process is available at the following link:https://www.gov.uk/government/publications/uk-nsc-annual-call-submitting-a-screening-proposal/uk-nsc-annual-call-how-to-submit-a-proposal

Whether his Department has made an assessment of the the potential merits of implementing routine screening for Type 1 Diabetes to reduce the incidence of diabetic ketoacidosis at diagnosis.

In the United Kingdom, national screening programmes are introduced based on the recommendations of the UK National Screening Committee (UK NSC), an independent scientific advisory committee which advises Ministers and the National Health Service in all four countries on all aspects of population and targeted screening and supports implementation.A proposal for screening for neonatal diabetes mellitus was submitted to the UK NSC via its 2021 annual call process. An evidence-mapping exercise was conducted at that time which concluded that there was not sufficient evidence to recommend screening for this condition.We are aware that the UK NSC received a submission via its 2024 annual call process to consider screening for autoimmune Type 1 Diabetes through blood testing. The UK NSC is currently reviewing all annual call proposals. More information on the annual call process is available at the following link:https://www.gov.uk/government/publications/uk-nsc-annual-call-submitting-a-screening-proposal/uk-nsc-annual-call-how-to-submit-a-proposal

What steps his Department is taking to ensure individuals with type one diabetes and disordered eating have access to integrated care for both their (a) physical and (b) mental health needs.

The National Health Service recognises the impact that type 1 diabetes with disordered eating can have on people and their families, which is why it has been piloting services to support those with the condition, and integrating care to help people improve their confidence and ability to manage their diabetes alongside their mental wellbeing. These pilots have shown improved outcomes for patients and cost effectiveness, and the NHS has now expanded sites to every region of the country, so that even more people can benefit from them.The Department, in partnership with NHS England and the Royal College of Psychiatrists, produced the Medical Emergencies in Eating Disorders guidance in May 2022, which has a full annexe on type 1 diabetes and eating disorders, and they are currently working to roll out the guidance to all systems.NHS England is continuing to expand community-based eating disorder service capacity, including crisis care and intensive home treatment, to improve outcomes and recovery, reduce rates of relapse, prevent eating disorders continuing into adulthood and, if admission is required as a very last resort, reduce lengths of stay. NHS England has asked local health systems, through this year’s NHS operational planning guidance, to focus on improving performance against the waiting time standards for children’s eating disorders services of 95% of urgent cases seen within one week, and 95% of routine cases seen within four weeks.

What steps his Department is taking to help develop guidelines for (a) general practitioners and (b) diabetes care teams on managing type one diabetes and disordered eating.

The National Health Service recognises the impact that type 1 diabetes with disordered eating can have on people and their families, which is why it has been piloting services to support those with the condition, and integrating care to help people improve their confidence and ability to manage their diabetes alongside their mental wellbeing. These pilots have shown improved outcomes for patients and cost effectiveness, and the NHS has now expanded sites to every region of the country, so that even more people can benefit from them.The Department, in partnership with NHS England and the Royal College of Psychiatrists, produced the Medical Emergencies in Eating Disorders guidance in May 2022, which has a full annexe on type 1 diabetes and eating disorders, and they are currently working to roll out the guidance to all systems.NHS England is continuing to expand community-based eating disorder service capacity, including crisis care and intensive home treatment, to improve outcomes and recovery, reduce rates of relapse, prevent eating disorders continuing into adulthood and, if admission is required as a very last resort, reduce lengths of stay. NHS England has asked local health systems, through this year’s NHS operational planning guidance, to focus on improving performance against the waiting time standards for children’s eating disorders services of 95% of urgent cases seen within one week, and 95% of routine cases seen within four weeks.

Whether he has made an assessment of the potential impact of the expiry of funding for T1DE pilot services on the health and well-being of patients in (a) Bournemouth and (b) London.

The National Health Service recognises the impact that type 1 diabetes with disordered eating can have on people and their families, which is why it has been piloting services to support those with the condition, and integrating care to help people improve their confidence and ability to manage their diabetes alongside their mental wellbeing. These pilots have shown improved outcomes for patients and cost effectiveness, and the NHS has now expanded sites to every region of the country, so that even more people can benefit from them.The Department, in partnership with NHS England and the Royal College of Psychiatrists, produced the Medical Emergencies in Eating Disorders guidance in May 2022, which has a full annexe on type 1 diabetes and eating disorders, and they are currently working to roll out the guidance to all systems.NHS England is continuing to expand community-based eating disorder service capacity, including crisis care and intensive home treatment, to improve outcomes and recovery, reduce rates of relapse, prevent eating disorders continuing into adulthood and, if admission is required as a very last resort, reduce lengths of stay. NHS England has asked local health systems, through this year’s NHS operational planning guidance, to focus on improving performance against the waiting time standards for children’s eating disorders services of 95% of urgent cases seen within one week, and 95% of routine cases seen within four weeks.

What estimate he has made of GP-to-patient ratios in (a) Harrogate and Knaresborough constituency and (b) North Yorkshire in each of the last five years.

Each general practice (GP) is required to provide services to meet the reasonable needs of their patients. There is no recommendation from NHS England for how many patients a GP should have assigned, or the ratio of GPs or other practice staff to patients...

What steps his Department is taking to help increase the early diagnosis rate for bowel cancer.

The Department is taking steps to improve the rate of early diagnosis for all cancers, including bowel and bowel-related cancers. We will support the National Health Service to transform diagnostic services by spending £1.5 billion on new surgical hubs an...

What steps his Department is taking to help improve outcomes for bowel cancer.

The National Health Service is taking crucial steps to improve cancer outcomes for patients across England, including for bowel cancer. We will improve cancer survival rates and hit all NHS cancer waiting time targets, so no patient waits longer than they...

What steps he is taking to reduce waiting times for the (a) diagnosis and (b) treatment of bowel cancer.

Lord Darzi’s report has set out the scale of the challenges we face in fixing the National Health Service, and the need to improve cancer waiting time performance and cancer survival. In particular, he has highlighted the need to improve the number of pat...